NBIX Neurocrine Biosciences
$145.51 +0.90%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
+0.90%
YTD
+6.20%
P/E
20.75
P/B
4.35
ROE
21.1%
Div yield
—
Beta
0.63
Market cap
$14.6B
RSI (14)
46
Next earnings
Oct 26, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$145.56
Close
$145.51
VWAP (n/a)
—
Day high
$145.77
Day low
$141.39
Volume
1.4M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Yahoo Finance · Sep 30
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Yahoo Finance · Sep 23
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
Yahoo Finance · Sep 18
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
Yahoo Finance · Sep 8
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Yahoo Finance · Sep 2
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
Yahoo Finance · Aug 28
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 28, 2026 View → 10-Q Jul 31, 2026 View → 8-K Jul 30, 2026 View → 8-K May 28, 2026 View → 8-K May 18, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell NBIX. Try it in the Lab to size a position and see the risk.